Life Sciences

Pharma Engagement Strategy: Embedding in Clinical Pathways

Share this post:

Clinical pathways are formalized processes of care designed to reduce treatment variability. They can also be referred to as integrated care pathways (ICPs) or care maps. While every medical case is unique, payers and providers are attempting to standardize treatment since unnecessary variation is a major source of growing costs. These formalized processes may take the form of treatment guidelines, decision trees, and triage criteria. Many Integrated Health Systems (IHSs) are considering incorporating ICPs into their organizational strategy.

Clinical pathways serve to improve overall efficiency by:

  • Managing the quality of healthcare with the goal of improving outcomes, via standardized care processes and reduced variability in clinical practice
  • Promoting organized and efficient patient care based on evidence-based practices taking into account specific patient population considerations including access to medications and insurance coverage

Pathways recommend the best option from a pool of care guidelines to effectively regularize delivery efforts across their institution. By standardizing care with both a clinical and economic mindset, pathways are an important value-conscious care strategy for providers and payers. As clinical treatment guidelines and pathways are increasingly deployed, they have a growing impact on the quality of treatment and how it is delivered.

Implications of Clinical Pathways for Providers

Pathways have probably been most popular in the oncology space, due to a lack of quality metrics and generally high pharmaceutical costs. As pathways become are increasingly enforced, they pose to fundamentally change the role of physicians:

1. Maximize caregiver resource utilization

Pathways have led to improved coordination between caregivers by giving nurses the ability to pursue a pre-approved care treatment with minimal oversight. This saves physicians time which they can then use to improve patient care.

2. Change of provider decision-making power

It is imperative for health systems to gain physician buy-in when standardizing care.  Any efforts to force pathways on caregivers are likely to fail. As a result, the Chief Medical Officer is often responsible for pathway formation and implementation.

3. Shift in physician incentives

Clinical pathway implementation is expanding on a greater scale in regional markets as dominant local/regional payers encourage greater pathway adoption through increasing levels of financial reimbursement attached to provider pathway usage.

The characteristics of effective clinical pathways are designed by physicians; evidence-based, updated regularly, informed through a formal physician feedback mechanism, evaluated for key data points on an ongoing basis and monitored for minimum compliance.

Potential implications of Clinical pathways

Institution of clinical pathways at the system level can likely result in major changes to pharmaceutical and imaging usage.

  • Downward pressure on pharmaceutical volumes: Pathways are designed to regulate dosage and minimize the use of pharmaceuticals. Due to this increased regulation of physician behavior, pharmaceutical volumes may drop for select conditions with strong clinical pathways.
  • Decreasing latitude for off-label usage in certain areas as pathways dictate what types of pharmaceuticals should be used in certain situations, certain off-label treatments may become difficult for physicians to use.
  • Shift in the ‘key customer’ for adoption: Pathways will lead to shift of decision making power within the IDN (Integrated Delivery Networks) to be more centralized and at a higher level, thus making it challenging for pharma to sell drugs without demonstrating clear economic value for the IDN.
  • Evolving drug positioning needs: There will be a need to closely track the evolution of pathways and adapt product launch and positioning at the right time depending on the indication especially in specialty products.
  • Increased pathway development collaborations: Big pharma is fast moving towards collaborating with IDNs and payers to better help understand outcomes. Capitalizing on this trend will be key to maintain positioning in a transitioning environment.

IBM’s MarketScan Treatment Pathways is designed to help you work more efficiently by overlaying an online analytic interface onto large patient-level databases such as IBM® MarketScan®.  MarketScan Treatment Pathways supports cross-sectional and longitudinal analyses, descriptive reporting, iterative exploratory research and quick querying, allowing studies or portions of study work to be completed without the need for data intake, software, or custom programming.

With faster speed to answers, improved visualization of analytic insights and boosted propensity scoring, Treatment Pathways now allows healthcare researchers to:

  • Explore treatment sequences and transitions
  • View time lapses in therapy
  • Assess market share changes
  • Analyze attrition rates for retail/specialty pharmacy scripts and office-based therapy

Read more about IBM’s MarketScan Treatment Pathways by clicking here.

As systems advance, IHSs will influence prescribing behavior via protocol driven medicine to limit brand access. Thus, it is important to segment evolving IHSs early with a pathway lens. There has been a rapid uptick in health systems with advanced capabilities who are increasingly adopting clinical pathways/protocols. Therefore, it is imperative for pharma manufacturers to gain a seat at the table for development of clinical pathways and protocols.

Cognitive Transformation Leader, Healthcare & Life Sciences, IBM

More Life Sciences stories

The future of disease management – the opportunities and challenges of digital interventions

Today’s industries are being disrupted by software-driven innovations, as evidenced by Amazon’s impact in retail markets, Netflix’s success over traditional cable providers, and the upheaval in hospitality industry from online marketplaces such as Airbnb. It is hence no surprise that the healthcare industry is seeing a surge in the development of software driven products to […]

Continue reading

Advance precision medicine with trusted data and AI solutions

Advancing precision medicine to improve diagnoses and treatments relies largely on big data coming from many sources and instruments in volumes that we have never seen before. This exploding growth of data, represented by very large files and many complex data types, pose enormous challenges for researchers that are trying to make sense of all […]

Continue reading

Predictive Modeling for Pharma Marketers: The Personalization Prescription

There’s massive opportunity in the $1,200 billion world of pharmaceutical marketing, and substantive shifts are underway as big data increases scope and narrows focus. Pharma marketers now face the challenge of combining high-level, abstract knowledge with personalized recommendations tailored to patient and health care provider (HCP) needs. Existing sales strategies and current categorization methods are […]

Continue reading